Post-Test on T2DM Back-to-Basics Special Report

Try these 10 questions and see what you've learned during this month's special report on the nuts-and-bolts of T2DM for PCPs.

This month’s Special Report has reviewed many of the basics of diagnosing and managing type 2 diabetes (T2DM), the care of which is provided largely by you and your primary care colleagues.

Specific installments have focused on clinical suspicion and screening at-risk patients; the tendency for clinical inertia when treating T2DM; the imperative to manage common comorbidities; teaching self-monitoring of blood glucose and using results to fine-tune treatment; and, recognizing when non-medical therapy and oral drugs are no longer sufficient to control hyperglycemia.

In the Introduction to the Special Report, you took a short pretest to determine what you already knew about the challenges of T2DM management.

Now is your chance to see the questions again in our post-test so you can gauge what you’ve learned, or been reminded about, in the management of T2DM from reading the T2DM Back-to-Basics for Primary Care Special Report sections.

Good luck!


Question 1:


Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology - Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan. Endocr Prac. 2015;21(suppl 1):S1-87.

American Diabetes Association Standards of Medical Care in Diabetes – 2017. Diabetes Care 2017; 40 (sup 1):S1-S138.


To review the full Special Report:

Introduction and Pre-test:  Type 2 Diabetes: What Busy PCPs Need to Know

Part 2:Type 2 Diabetes: Clinical Suspicion and Diagnosis

Part 3: Type 2 Diabetes: After the Diagnosis, Resist Inertia

Part 4:Self-monitoring Blood Glucose in T2DM: It's Essential

Part 5. T2DM: Intensifying Rx When Diet, Lifestyle and OADs Aren't Enough

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2023 MJH Life Sciences

All rights reserved.